Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

Opinion|Videos|January 31, 2025

Current and emerging treatments for PPD

Melanie Barrett, MD; Anita Clayton, MD, and Carmen Kosicek, MSN, PMHNP-BC, discuss how postpartum depression treatments are evolving beyond traditional antidepressants to include rapid-acting options like brexanolone and zuranolone, along with enhanced screening and support programs for new mothers.

Episodes in this series

1 expert is featured in this series.

EP. 1 Overview of Postpartum Depression

1 expert is featured in this series.

EP. 2 Real-World Patient Perspective: Navigating Care for PPD

1 expert is featured in this series.

EP. 3 Real-World Patient Perspective: Breaking the Stigma of PPD and Seeking Support

1 expert is featured in this series.

EP. 4 Diagnostic Tools For PPD

1 expert is featured in this series.

EP. 5 Current and emerging treatments for PPD

1 expert is featured in this series.

EP. 6 A case of a mother experiencing PPD at 12 weeks postpartum

1 expert is featured in this series.

EP. 7 Treatment approach for a mother experiencing PPD at 12 weeks postpartum

1 expert is featured in this series.

EP. 8 A case of a mother experiencing PPD while on low-dose SSRI

1 expert is featured in this series.

EP. 9 Treatment approach for a mother experiencing PPD already on SSRI

postpartum depression

EP. 10 Panel Discusses Screening, Treatment, and Challenges for Postpartum Depression

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Latest CME

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

Ilan Melnick, MD; Alejandro Alva, MD; Linda Trinh, DNP, PMHNP, FNP, MPH

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

Sanjai Rao, MD, DFAPA; Dawn I. Velligan, PhD

Southern Florida Psychiatry Conference

In-Person Event

Southern Florida Psychiatry Conference

November 21-22, 2025

Real Psychiatry 2026

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Optimizing Care for Patients With Tardive Dyskinesia

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

(CME Track) Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

(CME Track) Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CME Track) Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

(Pharmacist Track) Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(Pharmacist Track) Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

(Pharmacist Track) Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

ADHD Found Connected to Substance Use Disorder, With Sex Prevalence Differences

Lithium-Loaded Gold Nanoparticle Nasal Spray to Treat Neuropsychiatric Diseases

Sleep as Connective Tissue: Quantifying Team Dynamics in Elite Sports

A Moral Injury Update: The PNHP Study and an Imminent Step Toward Peace in the Mideast

Today Is World Mental Health Day: How Is Yours?

© 2025 MJH Life Sciences^®

All rights reserved.